New narcolepsy drug VX-433 enters first human safety tests
NCT ID NCT07584434
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage study tests a new drug called VX-433 in 118 people with narcolepsy type 1. The main goal is to check if it is safe and how the body processes it. Researchers will also see how VX-433 interacts with other drugs like midazolam and bupropion. This is a first step to see if VX-433 could one day help control narcolepsy symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VX-433
- What this could lead to
- If successful, this could lead to a new treatment option for narcolepsy type 1, helping control symptoms like sudden sleep attacks.
- What could go wrong
- This is a very early Phase 1 trial focused on safety, not effectiveness. It may fail to show benefit or have side effects. Results are years away from any possible treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NARCOLEPSY TYPE 1 (NT1) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON - Utah - Salt Lake City Office
RECRUITINGSalt Lake City, Utah, 84124, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.